Humedics aims to improve the overall outcomes for patients with liver disease by enabling physicians‘ clinical decision making through fast and accurate information about real-time liver function capacity.

About Humedics

Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient  and to improve patient outcomes.

LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.


Management - CEO

Chalom Sayada

Chalom Sayada, MD, Ph.D.

As managing director of Humedics GmbH, Dr. Chalom Sayada brings to 25 years of leadership experience in diagnostic product development and proven success in commercial launch and lifecycle management.

Dr. Sayada began his career at Paris Robert Debre Medical School as a molecular biologist in microbiology and human genetics researcher. Dr. Sayada was granted several international peer reviewed articles, and received several research grants in France and Europe, in the area of Chlamydia genotyping and Virology drug resistance managements.

In the early-1990’s Dr. Sayada moved into the Diagnostic industry at Roche Diagnostics in France, where his contributions led to accelerated commercialization of the first infectious disease molecular diagnostics suite of Products, Amplicor from Roche Molecular, in France, and in Europe indicated for monitoring of adults and children with HIV-1, HepC, Chlamydia and Tuberculosis infection, and diagnosis of HIV & HCV RNA in blood banks in France.

Over the years, Dr. Sayada has formed and led several new biotechnology companies, in Molecular diagnostics and in Therapeutics Development, in Europe and in the US, to develop innovative diagnostics, antivirals and antibiotics products, leading to several successful registrations and commercializations.

Since 2006, Dr. Sayada has been leading ABL SA to build a fully integrated Diagnostic company, from R&D, to manufacturing, regulatory, marketing and commercial, with the focus to develop proprietary innovative molecular diagnostics and IT medical software and solutions, in Infectious diseases.

Dr. Sayada serves as an Independent Director for GenosciencePharma SA (France) and Qode Healthcare Solutions (South Africa).

He holds a PhD in Microbiology from the University of Chatenay Malabry in south of Paris, and a MD from Paris Robert Debre Hospital University where he trained as a microbiology molecular biologist.



Finance & Controlling Manager

Kajo Wiest

Kajo Wiest is Finance Manager of the Humedics GmbH and brings more than 15 years of finance and controlling experiences.

He was Director Controlling at Jerini AG. During his time at Jerini, he was responsible for the establishment of controlling structures as well as supporting the company’s IPO and the sale of its wholly-owned subsidiary JPT, where he served as Finance Manager afterwards.

Before he joined Humedics he worked as Director Finance& Controlling for Magforce AG.


Board Members

Gilles Bos

An engineer by passion, an entrepreneur at heart

As an entrepreneur and engineer, I have over 30 years of experience in corporate management and technology development in the MedTech field.
A common thread guides my career choices; combining innovation and strategy in order to match product benefits with the market’s requirements. With this purpose in mind, in 2003, bolstered by years of experience in health care, I created a start-up company in collaboration with my partners, known as Anteis.
By awarding, my contribution to the industry in 2008 in the “HIGH-TECH AND BIOTECH” category, the experts of the Swiss Economic Forum honored the exceptional services of Anteis in the following fields: innovation, creativity, quality of services, job creation, technological advantage, research and development, and more.

Within 10 years, through focus on developing, manufacturing and marketing injectable Hyaluronic Acid, Anteis became known as a global leader in this particular field. Anteis was acquired by Merz Pharma in 2013.

Since 2013, I have focused on the financing and development of SMEs in various sectors through our global platform, now known as Medaesthetis. I recognize in Medaesthetis a real capacity to propose new technologies for Medical and Aesthetic treatments. Contributing to the projects on a daily basis, I bring my vision and expertise helping the teams to give their best for the satisfaction of our partners and clients.

Thomas Möller

Thomas Moeller is a general partner of BioMedPartners AG, which focuses on investments in life sciences in the DACH region. Thomas has been a venture capitalist for the last 17 years. Before joining BioMedPartners in 2003, he worked as Chief Financial Officer at NMT New Medical Technologies and as a Senior Manager at PricewaterhouseCoopers in Switzerland and the United States. Mr. Moeller has a degree as Swiss certified public accountant in 1996 as well as a master degree in economics and business administration from the University of Basel in 1991.

Klaus Stöckemann, PhD, MBA

Dr. Klaus Stöckemann is a co-founder and managing partner of Peppermint VenturePartners, which focuses on investments in medical device and digital-health start-up companies in Germany and Europe. He is an experienced venture capitalist with more than 15 years of experience, including a role as a general partner at 3i Healthcare Venture Capital. Stoeckemann has also worked at Schering AG (now Bayer) and Asta Medica (Degussa), and is a member of the board of the German Association of Venture Capital (BVK).

Medical Advisory Board

Prof. Dr. Peter Galle (Lead)
Prof. Dr. Hauke Lang
Prof. Dr. Guido Gerken
Prof. Dr. Hans J. Schlitt
Prof. Dr. Ali Canbay
Prof. Dr. Stefan Fichtner-Feigl

Founders & Scientific Advisory Board

Prof. Dr. Karsten Heyne

Karsten Heyne is one of the co-founders of Humedics GmbH. He is a Professor at the Free University of Berlin, with a focus on ultrafast spectroscopy in biologically-relevant systems. His research investigates electronic and structural changes as well as the specific manipulation of special organic molecule groups.

Prof. Dr. Martin Stockmann

Martin Stockmann is one of the co-founders of Humedics GmbH, and continues to provide advice and support to the management team on medical-related issues. He is chief physician at the clinic for general, visceral and vascular surgery at the Evangelical Hospital Paul Gerhardt Stift in Wittenberg. He leads the Workgroup for the Liver, looking at improving recovery of patients after liver surgery and transplantation. Stockmann has published over 100 articles in the field of liver function testing.



Martin Stockmann, MD, PhD, an abdominal surgeon at the Berlin Charité University medical centre, created the LiMAx test in 2001 and founded the workgroup for the liver.

Karsten Heyne, a professor at the department of physics, Free University of Berlin, conducted the technical development of the LiMAx test.

Humedics was founded in 2009, and the company began development of the LiMAx prototype, with initial capital provided by the High Tech Gründerfonds. Today, Humedics has about 10 employees and scale up production development is ongoing. In May 2011, Humedics successfuly completed a second round of founding, with Charité Biomedical Fonds, KfW, VC Fonds Technologie Berlin and Ventegis Capital AG joining as investors.